RecruitingPhase 2NCT02919644

Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.

Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer: a Phase II Study


Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Enrollment

19 participants

Start Date

Dec 2, 2016

Study Type

INTERVENTIONAL

Conditions

Summary

Single-arm, monocentric trial to assess safety and immunological efficacy of adjuvant vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer


Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study tests a personalized cancer vaccine made from a patient's own tumor cells for people with stage IV colorectal cancer (bowel cancer that has spread) who have had surgery to remove all visible cancer, to see if the vaccine can prevent the cancer from coming back. **You may be eligible if...** - You have been diagnosed with stage IV colorectal cancer - You have had surgery with the intent to remove all cancer (radical resection) - You are currently cancer-free as confirmed by recent imaging (CT or MRI) - Your tumor tissue was successfully collected and processed for vaccine preparation **You may NOT be eligible if...** - There is still detectable cancer in your body after surgery - Your tumor tissue could not be collected or processed for the vaccine - You are not in adequate health to receive the vaccine This innovative approach uses the immune system, trained on your own cancer cells, to attack any remaining cancer that might not be visible yet. Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALautologous dendritic cells loaded with autologous tumour homogenate

Each vaccine dose consists of 10\_7 autologous dendritic cells loaded with autologous tumor homogenate

DRUGIL2

Each vaccine dose is followed, after two days, by IL-2 as adjuvant, at a dose of 3 MU daily for five consecutive days


Locations(2)

UO Immunoterapia e Laboratorio TCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) S.r.l IRCCS

Meldola, FC, Italy

CRO-IRCCS Aviano

Aviano, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02919644